GSK (LON:GSK) Price Target Raised to GBX 1,660 at Berenberg Bank

GSK (LON:GSK) had its price objective upped by Berenberg Bank from GBX 1,600 to GBX 1,660 in a research report report published on Monday,London Stock Exchange reports. They currently have a hold rating on the stock.

Several other research analysts also recently commented on the stock. Shore Capital restated a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a research report on Monday, October 20th. JPMorgan Chase & Co. increased their target price on shares of GSK from GBX 1,400 to GBX 1,500 and gave the stock an “underweight” rating in a research note on Friday, November 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 1,450 price objective on shares of GSK in a report on Thursday, July 31st. Finally, Jefferies Financial Group increased their price objective on shares of GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a research note on Monday, November 3rd. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of GBX 1,762.

GSK Price Performance

Shares of GSK stock traded up GBX 1 during trading hours on Monday, reaching GBX 1,795. 9,696,659 shares of the company were exchanged, compared to its average volume of 11,580,692. The company has a market cap of £72.15 billion, a price-to-earnings ratio of 13.50, a P/E/G ratio of 1.24 and a beta of 0.31. GSK has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 1,830. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The stock’s fifty day moving average is GBX 1,660.24 and its two-hundred day moving average is GBX 1,513.91.

GSK (LON:GSK) last posted its earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Sell-side analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Buying and Selling at GSK

In other news, insider Wendy Becker purchased 526 shares of the stock in a transaction on Friday, September 19th. The shares were acquired at an average price of GBX 1,503 per share, with a total value of £7,905.78. In the last 90 days, insiders have acquired 558 shares of company stock worth $840,455. Company insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.